Cancers Associated with BRCA1 and BRCA2 Gene Mutations
BRCA1 and BRCA2 mutations are definitively associated with breast cancer (female and male), ovarian cancer (including fallopian tube and peritoneal), pancreatic cancer, and prostate cancer (primarily BRCA2), with BRCA2 mutations conferring broader cancer risks than BRCA1. 1, 2
Primary Cancer Associations
Female Breast Cancer
- BRCA1: Cumulative lifetime risk up to 70-80% by age 70
- BRCA2: Cumulative lifetime risk up to 70-80% by age 70
- BRCA1-associated breast cancers are typically triple-negative, high-grade tumors 1
- BRCA2-associated breast cancers show more variable histology 1
Ovarian, Fallopian Tube, and Peritoneal Cancer
- BRCA1: 48.3% cumulative risk by age 70 (95% CI, 38.8%-57.9%)
- BRCA2: 20.0% cumulative risk by age 70 (95% CI, 13.3%-29.0%)
- Predominantly high-grade serous adenocarcinoma histology 1
- Important caveat: Mucinous, borderline, and non-epithelial ovarian tumors are NOT associated with BRCA1/2 mutations 1
Male Breast Cancer
- BRCA2: 7-8% lifetime risk (RR = 44.0; 95% CI, 21.3-90.9) - this is the strongest association
- BRCA1: 1.2% lifetime risk (RR = 4.30; 95% CI, 1.09-16.96)
- Compare to 0.1% baseline risk in non-carriers 1, 2
Pancreatic Cancer
- BRCA2: Approximately 2.5% absolute risk to age 80 (RR = 3.34; 95% CI, 2.21-5.06)
- BRCA1: Approximately 2.5% absolute risk to age 80 (RR = 2.36; 95% CI, 1.51-3.68)
- Both genes show significant associations 1, 2, 3
Prostate Cancer
- BRCA2: 27% absolute risk to age 80 (RR = 2.22; 95% CI, 1.63-3.03) - clinically significant association
- BRCA1: Increased risk but less well-characterized than BRCA2
- BRCA2 carriers develop more aggressive disease 1, 2, 3
Secondary Cancer Associations
Stomach Cancer
- BRCA2: RR = 3.69 (95% CI, 2.40-5.67), with higher risk in females (RR = 6.89) than males (RR = 2.76)
- BRCA1: RR = 2.17 (95% CI, 1.25-3.77)
- These associations are supported by the most recent large-scale analysis 2
Other Possible Associations
The 2021 NCCN guidelines 1 and recent research 2 suggest:
- Colorectal cancer: Possible association with BRCA1, but evidence is limited
- Gallbladder cancer: Suggested association with BRCA1
- Melanoma: Possible association with BRCA2 4
Key Clinical Distinctions Between BRCA1 and BRCA2
BRCA2 confers a broader cancer spectrum and higher overall cancer risk in males compared to BRCA1 4, 3:
- BRCA2 males have particularly elevated risks before age 65
- BRCA2 is associated with male breast, prostate, pancreatic, and stomach cancers
- BRCA1 primarily affects breast cancer risk in both sexes, with moderate increases in ovarian and pancreatic cancer
Important Clinical Caveats
Not all ovarian tumors are associated: Borderline tumors, mucinous carcinomas, and non-epithelial ovarian cancers show NO significant association with BRCA1/2 1
Tubal origin: Many "ovarian" cancers in BRCA carriers actually originate in the fallopian tube fimbriae, with tubal intraepithelial carcinoma (TIC) detected in 5-8% of risk-reducing surgeries 1
Male carriers are underrecognized: Despite significant cancer risks, males undergo genetic testing far less frequently than females 3
Other genes to consider: The guidelines 5 note that moderate- to high-penetrance mutations in PALB2, CHEK2, ATM, RAD51C, RAD51D, BRIP1, and mismatch repair genes (MLH1, MSH2, MSH6, PMS2) may also increase breast/ovarian cancer risk